Diasorin SpA's Total Assets for the quarter that ended in Dec. 2025 was €2,873 Mil.
Warning Sign:
If a company builds assets at 16.7% a year, faster than its revenue growth rate of 3.6% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Diasorin SpA's average Total Assets Growth Rate was -8.50% per year.
During the past 3 years, the average Total Assets Growth Rate was -3.80% per year.
During the past 5 years, the average Total Assets Growth Rate was 16.70% per year.
During the past 10 years, the average Total Assets Growth Rate was 22.40% per year.
During the past 13 years, Diasorin SpA's highest 3-Year average Total Assets Growth Rate was 51.70%. The lowest was -3.80%. And the median was 12.40%.
Note:
The Net Income data used here is four times the quarterly (Dec. 2025) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Diasorin SpA's Asset Turnover for the quarter that ended in Dec. 2025 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Diasorin SpA Total Assets Related Terms
Diasorin SpA Total Assets Historical Data
* Premium members only.
The historical data trend for Diasorin SpA's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Diasorin SpA's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diasorin SpA (MIL:DIA) has a Total Assets of €2,873 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Diasorin SpA and its competitors.
Is Diasorin SpA's Total Assets too high?
Diasorin SpA's current Total Assets is €2,873 Mil. Overall, Diasorin SpA has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diasorin SpA's Total Assets compare to TMO and DHR?
Diasorin SpA's Total Assets of €2,873 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Medical Diagnostics & Research company?
A good Total Assets depends on the Medical Diagnostics & Research industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Diasorin SpA and its competitors. Diasorin SpA's current Total Assets is €2,873 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diasorin SpA stock overvalued right now?
Based on GuruFocus' analysis, Diasorin SpA (MIL:DIA) is currently considered Modestly Undervalued. The stock's GF Value™ is €90.16, compared to a current price of €67.76 — trading 24.8% below its estimated fair value. The current Total Assets is €2,873 Mil. Diasorin SpA's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Diasorin SpA (MIL:DIA), the current Total Assets is €2,873 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diasorin SpA (MIL:DIA) Overvalued in 2026?
Based on GuruFocus' analysis, Diasorin SpA stock appears to be undervalued.
The current stock price of €67.76 is trading 24.8% below its estimated GF Value™ of €90.16.
GuruFocus considers Diasorin SpA to be Modestly Undervalued.
Key valuation signals for MIL:DIA:
Total Assets: €2,873 Mil
GF Value™: €90.16 vs. price of €67.76 (24.8% below fair value)
No single metric tells the full story. See the MIL:DIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diasorin develops and manufactures a broad portfolio of in vitro diagnostics for detecting pathogens and sample contamination from the human body, as well as for use in industrial settings, such as food and water contamination testing. The company operates three segments: immunodiagnostics (69% of sales), molecular diagnostics (16%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment's importance has decreased over the years, and in 2025, it accounted for only 1% of total sales.
69GF Score
Get the complete analysis for MIL:DIA
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:DIA has been successfully added to your 
